$THC

KERREY J ROBERT sold $125K of THC

KERREY J ROBERT sold 713 shares of TENET HEALTHCARE CORP (THC) at $175.13 ($0.12M total) on 2026-05-28.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 30, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Neutral
low confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides incremental information about insider behavior but does not include new company performance, guidance, or legal/contract developments.

02

Market read

Traders may briefly reassess sentiment around THC due to insider selling, but the event lacks fundamental linkage in the filing.

03

What to watch

No 10b5-1 plan is indicated, so traders may over-interpret; also the disclosed sale size is relatively small versus typical institutional flows.

Relevance 6/10Novelty 6/10Timing: Filed 2026-05-29 for a sale executed 2026-05-28

Background

SEC Form 4 reports insider transactions by directors/officers/10%-owners; markets often treat these as sentiment signals rather than fundamental drivers.

Company-level read

Ticker impact

$THCNeutralLow confidence
Context

Tenet Healthcare director Kerrey J. Robert sold 713 shares in an open-market transaction for ~$124.9K at $175.13 on 2026-05-28.

Expected impact

Low near-term impact; any move is likely limited unless accompanied by other news.

Evidence & confidence

This is a routine Form 4 insider sale with no 10b5-1 plan stated; size is modest and there is no accompanying operational/financial update.

Market effects

Minimal; single-company insider sale typically does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Director sales can be driven by diversification, taxes, or scheduled liquidity needs rather than bearish fundamentals.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider sale by a director.

  • Kerrey J. Robert

    Director who sold 713 shares of THC for ~$124.9K.

Related articles

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

$THCMedAI 8/10

Why Tenet Healthcare Stock Is Soaring Today

Tenet Healthcare (THC) shares rose after the company reported fiscal Q2 results and raised 2026 guidance. For the quarter ended in June, revenue was $5.63B and adjusted EPS was $6.12, both above year-ago figures and analyst estimates ($5.43B revenue, $4.26 EPS). 2026 revenue guidance increased to $21.9B-$22.5B and adjusted EBITDA to $4.83B-$5.03B.